Literature DB >> 1737439

Comparison of susceptibility to beta-lactam antimicrobial agents among bacteria isolated from intensive care units.

C L Pierson1, B A Friedman.   

Abstract

Evaluating microbial isolation and susceptibility patterns from institutional settings is a well-established component of ongoing infection control activities. At the University of Michigan Hospitals, susceptibility profiles for selected bacteria tested from 1984 to 1989 were analyzed for major changes in the percentage of organisms susceptible to beta-lactam antimicrobials. Data on bacteria isolated from respiratory specimens obtained from 1433 patients in intensive care units (ICUs) during a 10-month interval were compared with like data obtained from 750 non-ICU patients. Antimicrobial agents studied were chosen based on hospital formulary availability and prevailing usage in the institution. Susceptible and moderately susceptible categories were combined for purposes of reporting, since empiric therapeutic doses would cover strains having both susceptibility levels. Antimicrobic susceptibilities were compared and differences analyzed among the ICUs. Major shifts in susceptibility were noted during the 5-year period. The incidence and susceptibility profiles of the microorganisms varied considerably between ICU and non-ICU patients. Pseudomonas aeruginosa isolates from individual ICUs showed large variations in prevailing susceptibilities, with the burn unit harboring the most resistant strains. However, the neurological, surgical, and critical care medicine units also showed large numbers of antimicrobial-resistant pseudomonads. Among Enterobacter cloacae isolates, only imipenem showed a high level of activity against both ICU and total hospital isolates. When examined by individual ICU, however, imipenem resistance was seen in the general medicine and burn units. The burn and pediatric ICUs showed increased rates of recovery of beta-lactam-resistant E. cloacae isolates, although significantly high resistance rates were seen throughout all ICUs. The surgical ICU was noted to have an abnormally high incidence of lower respiratory infections caused by P. aeruginosa. The antibiogram indicated that one possible epidemic strain was involved. However, when the isolates were subjected to fatty-acid profiling by gas-liquid chromatography, it was found that cross-contamination with five discernible strains had occurred among the ten patients tested. These preliminary data suggest that resistant pseudomonads can be harbored and spread within an ICU, and that the ICU can act as a reservoir of resistance that is spread to a "step-down" unit.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1737439

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  6 in total

1.  Comparison of hospital-wide and unit-specific cumulative antibiograms in hospital- and community-acquired infection.

Authors:  F Lamoth; A Wenger; G Prod'hom; Y Vallet; C Plüss-Suard; J Bille; G Zanetti
Journal:  Infection       Date:  2010-06-16       Impact factor: 3.553

2.  Cumulative Antimicrobial Susceptibility Data from Intensive Care Units at One Institution: Should Data Be Combined?

Authors:  Aaron Campigotto; Matthew P Muller; Linda R Taggart; Reem Haj; Elizabeth Leung; Jeya Nadarajah; Larissa M Matukas
Journal:  J Clin Microbiol       Date:  2016-01-20       Impact factor: 5.948

3.  Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates from Intensive Care Units in the United States: a Potential Role for New β-Lactam Combination Agents.

Authors:  Tomefa E Asempa; David P Nicolau; Joseph L Kuti
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

Review 4.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 5.  Cost considerations in therapeutic drug monitoring of aminoglycosides.

Authors:  J S Bertino; K A Rodvold; C J Destache
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

6.  Comparison of Hospitalwide and Custom Antibiograms for Clinical Isolates of Pseudomonas aeruginosa.

Authors:  John A Bosso; Adam Sieg; Patrick D Mauldin
Journal:  Hosp Pharm       Date:  2013-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.